Neoantigens are unique markers that distinguish only cancer cells. By adding B cell reactivity, cancer vaccines can move ...

The fear of cancer stems from the dread that it can recur at any time, even after treatment. A South Korean research team has ...

Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During their preparation for this battle, B cells transiently revert to a more ...

As the world observes World Lymphoma Awareness Day on September 15th, it 39;s a timely reminder of the ongoing battle against ...

Non-Hodgkin lymphoma (NHL) is a form of cancer that begins in the lymph system. B-cell NHLs affect immune cells known as B lymphocytes or B cells. All forms of NHL begin in lymphocytes. These white ...

KAIST Professor Jung Kyoon Choi, Dr. Jeong Yeon Kim, and Dr. Jin Hyeon An >Neoantigens are unique markers that distinguish only cancer ...

B-cell prolymphocytic leukemia (B-PLL) is a rare, aggressive type of leukemia that progresses rapidly. People with B-PLL typically have a less favorable outlook. However, new targeted treatments in ...

As researchers race to identify new therapeutics, streamlined antibody discovery processes have never been more crucial, and the need for speed and efficiency is paramount. The development of ...

At the recent American Society of Hematology annual meeting, phase I data highlighted a next-generation, CD19-targeted, interleukin-18-secreting "armored" CAR T-cell therapy that is designed to ...

Intravascular large B-cell lymphoma (IVLBCL) is a rare type of non-Hodgkin’s lymphoma. Its symptoms can vary, making it difficult to diagnose. The outlook for people with IVLBCL is typically poor.